However, loss of p53 tumour-suppressor activity can also occur through amplification of MDM2. As MDM2 is a negative regulator of p53, this promotes p53 degradation and inhibits p53 tumour ...

Ziftomenib targets relapsed/refractory AML with NPM1 mutations, a condition with high relapse rates and poor survival outcomes. The drug has received breakthrough therapy, fast track, and orphan drug ...